NewsBenzingaHoneywell Technologies Debuts Forge Plant Cognition At Dangote’s Lekki Refinery, Estimating More Than 29 Cents A Barrel In Operational Benefit, Or Over $60M Per Year At Full Capacity Honeywell Technologies Debuts Forge Plant Cognition At Dangote’s Lekki Refinery, Estimating More Than 29 Cents A Barrel In Operational Benefit, Or Over $60M Per Year At Full Capacity Benzinga 2026.10.26 08:14 (GMT+0) Open on Benzinga Other news Trader Mk4's NEAR long shows $12.15M unrealized profit, long position worth over $25M Baron Health Care Fund Q3 2026 Top Contributors And Detractors Sturm, Ruger: Strategic Alliance With Beretta Supports Long-Term Growth (NYSE:RGR) Robert Reich Says Elon Musk’s SpaceX and Starlink Should Become Publicly Owned, Musk Fires Back: ‘Stealing Companies Is a Serious Crime' Bristol Myers Squibb, SystImmune’s Iza-Bren Hits Primary Endpoint In Phase 3 PANKU-Lung01 Interim Analysis, Median PFS 11.1 Versus 5.7 Months (HR 0.40) Over Platinum Chemotherapy In EGFR-Mutated NSCLC Reported Saturday, GSK’s Jemperli Monotherapy Shows Generally Consistent Safety, With Serious Adverse Reactions In 20% And Discontinuations In 3%, Alongside 76% Complete Response In Phase II AZUR-1 MSI-H/dMMR Rectal Cancer Trial
Robert Reich Says Elon Musk’s SpaceX and Starlink Should Become Publicly Owned, Musk Fires Back: ‘Stealing Companies Is a Serious Crime'
Bristol Myers Squibb, SystImmune’s Iza-Bren Hits Primary Endpoint In Phase 3 PANKU-Lung01 Interim Analysis, Median PFS 11.1 Versus 5.7 Months (HR 0.40) Over Platinum Chemotherapy In EGFR-Mutated NSCLC
Reported Saturday, GSK’s Jemperli Monotherapy Shows Generally Consistent Safety, With Serious Adverse Reactions In 20% And Discontinuations In 3%, Alongside 76% Complete Response In Phase II AZUR-1 MSI-H/dMMR Rectal Cancer Trial
